Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Alamar Biosciences, Inc.NASDAQ: ALMR
Operating Margin · Q2 FY2026 · quarter ended Jun 2026
Operating margin at -46.0%
Operating margin was -46.0% in Q2 FY2026.
What to watch
Whether operating margin reaches the consensus estimate from 3 analysts of -38.7% for the fiscal year ending Dec 2026, up from -42.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -46.0%+1.4 pp QoQ
- Last fiscal yearDec 2025
- -42.2%— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +3.5 pp | — |
| 3 years | — | +3.5 pp | — |
| 5 years | +3.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -42.2%
- Year-over-year change
- —
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -42.2% | — |
Operating Margin vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 operating margin of -42.2% is the 4th highest of the 8 companies compared; the peer median is -91.0%.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 19.6% | +10.6 pp | -5.6 pp | |
| LTM Sep 2026 | -11.7% | +2.6 pp | +15.3 pp | |
| LTM Sep 2026 | -30.4% | +5.8 pp | +58.2 pp | |
ALMRAlamar Biosciences, Inc. | FY2025 | -42.2% | — | — |
| LTM Mar 2026 | -91.0% | -2.5 pp | +9.3 pp | |
| LTM Mar 2026 | -101.7% | +437.7 pp | -109.0 pp | |
| LTM Mar 2026 | -496.4% | +134.5 pp | +180.9 pp | |
| LTM Mar 2026 | -5199.8% | -1995.4 pp | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ALMR) | -91.0% | +5.8 pp | +12.3 pp | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 74.21M |
| Cost of Revenue | 32.51M |
| Gross Profit | 41.71M |
| Gross Margin | 56.2% |
| Research & Development | 37.47M |
| Selling, General & Admin | 35.57M |
| Operating Expenses | 73.04M |
| Depreciation & Amortization | 3.86M |
| EBITDA | (24.89M) |
| EBITDA Margin | -33.5% |
| Operating Income | (31.33M) |
| Operating Margin | -42.2% |
| Interest Income | 2.16M |
| Interest Expense | 401K |
| Other Income / Expenses | 2.18M |
| Income Before Tax | (29.15M) |
| Pre-Tax Margin | -39.3% |
| Income Tax Expense | 665K |
| Net Income | (29.82M) |
| Net Margin | -40.2% |
| EPS (Basic) | (0.45) |
| EPS (Diluted) | (0.45) |
| Weighted Avg Shares | 66.52M |
| Weighted Avg Shares (Diluted) | 66.52M |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.